High dose IL-2 in the treatment of metastatic melanoma and metastatic renal cell carcinoma.

被引：0
|
作者：
Woodrum, T [1 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE USA
来源：
ONCOLOGY NURSING FORUM | 2004年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
86
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [31] Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2
    Brian Khong
    Benjamin O. Lawson
    Junjie Ma
    Cheryl McGovern
    Joan K. Van Atta
    Abhijit Ray
    Hung T. Khong
    BMC Cancer, 18
  • [32] Metastatic renal cell carcinoma. Primary and follow-up treatment
    Steiner, T.
    Mickisch, G. H.
    UROLOGE, 2013, 52 (11): : 1529 - +
  • [33] Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma.
    Park, Inkeun
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Jeong, In Gab
    Song, Cheryn
    Hong, Bum-Sik
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] Treatment facility volume and survival in patients with metastatic renal cell carcinoma.
    Geynisman, Daniel M.
    Handorf, Elizabeth
    Zibelman, Matthew R.
    Plimack, Elizabeth R.
    Uzzo, Robert
    Kutikov, Alexander
    Smaldone, Marc C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2
    Khong, Brian
    Lawson, Benjamin O.
    Ma, Junjie
    McGovern, Cheryl
    Van Atta, Joan K.
    Ray, Abhijit
    Khong, Hung T.
    BMC CANCER, 2018, 18
  • [36] Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Buchbinder, Elizabeth I.
    Dutcher, Janice P.
    Daniels, Gregory A.
    Curti, Brendan D.
    Patel, Sapna P.
    Holtan, Shernan G.
    Miletello, Gerald P.
    Fishman, Mayer N.
    Gonzalez, Rene
    Clark, Joseph I.
    Richart, John M.
    Lao, Christopher D.
    Tykodi, Scott S.
    Silk, Ann W.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] Immunotherapy in metastatic renal cell carcinoma. With special regard to treatment of the elderly
    Heinzer, H
    Huland, E
    Huland, H
    UROLOGE A, 2003, 42 (11): : 1450 - 1452
  • [38] Treatment of metastatic renal cell carcinoma. Immunotherapy versus surgical removal
    Heinzer, H
    Huland, E
    Huland, H
    UROLOGE A, 2000, 39 (04): : 356 - 361
  • [39] A novel strategy for axitinib dosing in the treatment of metastatic renal cell carcinoma.
    Doherty, Gary
    Lynskey, Deirdre
    Matakidou, Athena
    Fife, Kate
    Eisen, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [40] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2)
    Straubhar, Alli M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Crispin, Hilda
    Sendlinathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Agarwal, Archana M.
    Tantravahi, Srinivas Kiran
    Samiowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345